Table 3.

Immune‐related adverse events grouped per incidence ^†

Most common >15%	Less common 2–15%	Uncommon <1–2%
Mild rash	Rash (combo IO)	Severe skin toxicity
Mild diarrhoea	Colitis	Hypophysitis (single agent nivolumab)
Thyroid dysfunction requiring hormone replacement	Mild–moderate hepatitis	Severe hepatitis
	Pneumonitis	Insulin dependent diabetes
	Hypophysitis (combo IO)	Colonic perforation
	Mild or moderate arthralgias	Severe or life‐threatening dyspnoea
	Mild or moderate renal toxicity	Neurological AE
		Other rheumatologic AE (vasculitis, polymyositis, myositis, temporal arteritis)
		Severe or life‐threatening renal dysfunction
		Cardiac toxicity
		Occular toxicity
		Haematological toxicity

^†Adapted from European Society Medical Oncology Clinical Practice Guidelines. ³⁴

AE, adverse events; combo, combination therapy; IO, immuno‐oncology.